The multi-panel test displayed a high sensitivity for CRC and HGD adenomas (71 and 23%, respectively) in the case of a positive result, which included those with ≥ 1 PCR replicates positive for either IKZF1 or IRF4, or at least two replicates positive for BCAT1, and a significantly improved specificity (94%) versus any PCR replicate positive. This evidence concerns the gene IKZF1 and colorectal carcinoma.